BullFrog AI details 2025 progress, pharma partnerships, and 2026 catalysts

BullFrog AI Holdings, Inc.

Annual cash burn ~$6.2M; $10M equity line and ATM provide financing flexibility.
Multiple advanced pharma discussions for out-licensing or discovery collaborations with upfront/milestone payments.
Sygnature Discovery collaboration expected to generate revenue through 2028; sales kickoff in Sept 2025.
Eleison data from late-stage oncology collaboration accepted for ASCO GI Cancers Symposium Jan 9, 2026.
Launched bfPREP data prep tool; reduces data prep from months to days, enabling earlier engagement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.